JF
TSHA icon

Jump Financial’s Taysha Gene Therapies TSHA Stock Holding History

Jump Financial’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-54,090
Closed -$155K – 2276
2024
Q1 		$155K Buy
+54,090
New +$113K ﹤0.01% 1740
2023
Q1 		– Sell
-16,917
Closed -$38.2K – 2071
2022
Q4 		$38.2K Buy
+16,917
New +$34.3K ﹤0.01% 1503
2022
Q2 		– Sell
-13,700
Closed -$89K – 2029
2022
Q1 		$89K Sell
13,700
-7,000
-34% -$52.3K ﹤0.01% 1426
2021
Q4 		$241K Buy
+20,700
New +$312K 0.02% 1010

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Jump Financial's TSHA Position: Q2 2024 in Review

Jump Financial sold out of Taysha Gene Therapies (TSHA) in Q2 2024, closing a stake of 54,090 shares — an estimated $155K sold.

Jump Financial first reported a position in TSHA in Q4 2021 and held it in 4 quarters. The position peaked at $241K in Q4 2021. 107 funds tracked by Wall St. Rank hold TSHA as of Q2 2024.

  • Jump Financial reported no remaining Taysha Gene Therapies position as of Q2 2024 after selling out during the quarter.
  • Jump Financial sold 54,090 Taysha Gene Therapies shares in Q2 2024, an estimated $155K.
  • Jump Financial first reported a position in Taysha Gene Therapies in Q4 2021 and held it in 4 quarters.
  • Jump Financial's Taysha Gene Therapies position peaked at $241K in Q4 2021.
  • 107 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2024.

Based on Jump Financial's 13F filing for Q2 2024, filed 14 Aug 2024.